David Fedida

David Fedida is a Professor and an Associate Head in the Department of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia. David Fedida obtained his B.S. and Ph.D. degrees at the University of Leeds in England in fundamental cardiac electrophysiology and his Medical degree from Oxford University. After two years spent in surgical and medical residencies, he spent postdoctoral periods at Oxford with Denis Noble, Wayne Giles in Calgary, and Arthur Brown at Baylor College of Medicine in Texas where he first identified the potassium ion channel, Kv1.5, as the molecular basis of the delayed rectifier, IKur, in human atrium. He returned to Canada in 2001 and is presently a Career Investigator of the Heart and Stroke Foundation of BC and Yukon, at UBC, where he leads a research group investigating atrial potassium channels and the remodeling of ion channels in disease. This work involves understanding cardiac electrical activity in health and disease. David Fedida has consulted for companies like Roche and Xenon Pharma, and with Cardiome Pharma Corp has been actively involved in the discovery and development of Vernakalant for the past eight years as a new treatment for the acute conversion of atrial fibrillation to sinus rhythm.

Biography Updated on 27 January 2008

Personal Home Page

http://www.cardiovascularresearch.ca/members/david-fedida

Articles in Scholarly Journals [Incomplete List]

  1. Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial Fibrillation
    Journal of Medicinal Chemistry, vol. 50, no. 12, pp. 2818–2841, 2007
  2. A Direct Demonstration of Closed-State Inactivation of K+ Channels at Low pH
    The Journal of General Physiology, vol. 129, no. 5, pp. 437–455, 2007
  3. Mechanisms of cardiac potassium channel trafficking
    The Journal of Physiology, vol. 582, no. 1, pp. 17–26, 2007
  4. Gating currents from a Kv3 subfamily potassium channel: charge movement and modification by BDS-II toxin
    The Journal of Physiology, vol. 584, no. 3, pp. 755–767, 2007
  5. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent
    Expert Opinion on Investigational Drugs, vol. 16, no. 4, pp. 519–532, 2007
  6. An Activation Gating Switch in Kv1.2 Is Localized to a Threonine Residue in the S2-S3 Linker
    Biophysical Journal, vol. 93, no. 12, pp. 4173–4186, 2007
  7. SCAM analysis reveals a discrete region of the pore turret that modulates slow inactivation in Kv1.5
    AJP: Cell Physiology, vol. 292, no. 3, pp. C1041–C1052, 2006
  8. 4-Aminopyridine Prevents the Conformational Changes Associated with P/C-Type Inactivation in Shaker Channels
    Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, pp. 162–172, 2006
  9. The Role of Late INa and Antiarrhythmic Drugs in EAD Formation and Termination in Purkinje Fibers
    Journal of Cardiovascular Electrophysiology, vol. 17, no. s1, pp. S71–S78, 2006
  10. Block by internal Mg2+ causes voltage-dependent inactivation of Kv1.5
    European Biophysics Journal, vol. 36, no. 1, pp. 23–34, 2006
  11. A specific N-terminal residue in Kv1.5 is required for upregulation of the channel by SAP97
    Biochemical and Biophysical Research Communications, vol. 342, no. 1, pp. 1–8, 2006
  12. Superoxide radical production by allopurinol and xanthine oxidase
    Biochemical Pharmacology, vol. 71, no. 12, pp. 1747–1752, 2006
  13. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents
    Cardiovascular Research, vol. 70, no. 3, pp. 486–496, 2006
  14. Localization of Kv1.5 channels in rat and canine myocyte sarcolemma
    FEBS Letters, vol. 580, no. 26, pp. 6039–6046, 2006
  15. A structural interpretation of voltage-gated potassium channel inactivation
    Progress in Biophysics and Molecular Biology, vol. 92, no. 2, pp. 185–208, 2006
  16. A Novel Mechanism for the Suppression of a Voltage-gated Potassium Channel by Glucose-dependent Insulinotropic Polypeptide: PROTEIN KINASE A-DEPENDENT ENDOCYTOSIS
    Journal of Biological Chemistry, vol. 280, no. 31, pp. 28692–28700, 2005
  17. KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor, Is a Direct Extracellular Blocker of Voltage-Gated Potassium Channels
    Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 1, pp. 292–299, 2005
  18. The Mechanism of Atrial Antiarrhythmic Action of RSD1235
    Journal of Cardiovascular Electrophysiology, vol. 16, no. 11, pp. 1227–1238, 2005
  19. Kv1.5 Surface Expression Is Modulated by Retrograde Trafficking of Newly Endocytosed Channels by the Dynein Motor
    Circulation Research, vol. 97, no. 4, pp. 363–371, 2005
  20. Modulation of Kv3 Subfamily Potassium Currents by the Sea Anemone Toxin BDS: Significance for CNS and Biophysical Studies
    Journal of Neuroscience, vol. 25, no. 38, pp. 8735–8745, 2005
  21. Single Channel Analysis Reveals Different Modes of Kv1.5 Gating Behavior Regulated by Changes of External pH
    Biophysical Journal, vol. 90, no. 4, pp. 1212–1222, 2005
  22. Constitutive Inactivation of the hKv1.5 Mutant Channel, H463G, in K+-Free Solutions at Physiological pH
    Cell Biochemistry and Biophysics, vol. 43, no. 2, pp. 221–230, 2005
  23. Synergistic Inhibition of the Maximum Conductance of Kv1.5 Channels by Extracellular K+ Reduction and Acidification
    Cell Biochemistry and Biophysics, vol. 43, no. 2, pp. 231–242, 2005
  24. Separation of P/C- and U-type inactivation pathways in Kv1.5 potassium channels
    The Journal of Physiology, vol. 568, no. 1, pp. 31–46, 2005
  25. Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay
    Journal of Biomolecular Screening, vol. 9, no. 7, pp. 588–597, 2004
  26. NH2-terminal Inactivation Peptide Binding to C-type-inactivated Kv Channels
    The Journal of General Physiology, vol. 123, no. 5, pp. 505–520, 2004
  27. Heterogeneous expression of repolarizing, voltage-gated K+ currents in adult mouse ventricles
    The Journal of Physiology, vol. 559, no. 1, pp. 103–120, 2004
  28. Modulation of human ether-a-go-go-related K+ (HERG) channel inactivation by Cs+ and K+
    The Journal of Physiology, vol. 548, no. 3, pp. 691–702, 2003
  29. Rapid Induction of P/C-type Inactivation Is the Mechanism for Acid-induced K+ Current Inhibition
    The Journal of General Physiology, vol. 121, no. 3, pp. 215–225, 2003
  30. SAP97 increases Kv1.5 currents through an indirect N-terminal mechanism
    FEBS Letters, vol. 547, no. 1-3, pp. 205–211, 2003
  31. Kv1.5 Is an Important Component of Repolarizing K+ Current in Canine Atrial Myocytes
    Circulation Research, vol. 93, no. 8, pp. 744–751, 2003
  32. N-terminal PDZ-binding domain in Kv1 potassium channels
    FEBS Letters, vol. 531, no. 3, pp. 529–537, 2002
  33. Amino-terminal Determinants of U-type Inactivation of Voltage-gated K+ Channels
    Journal of Biological Chemistry, vol. 277, no. 32, pp. 29045–29053, 2002
  34. Uncoupling of Gating Charge Movement and Closure of the Ion Pore During Recovery from Inactivation in the Kv1.5 Channel
    The Journal of General Physiology, vol. 120, no. 2, pp. 249–260, 2002
  35. Molecular determinants of the inhibition of human Kv1.5 potassium currents by external protons and Zn2+
    The Journal of Physiology, vol. 541, no. 1, pp. 9–24, 2002
  36. External K+ relieves the block but not the gating shift caused by Zn2+ in human Kv1.5 potassium channels
    The Journal of Physiology, vol. 532, no. 2, pp. 349–358, 2001
  37. Gating of voltage-dependent potassium channels
    Progress in Biophysics and Molecular Biology, vol. 75, no. 3, pp. 165–199, 2001
  38. Altered State Dependence of C-Type Inactivation in the Long and Short Forms of Human Kv1.5
    The Journal of General Physiology, vol. 118, no. 3, pp. 315–332, 2001
  39. a-Actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells
    FEBS Letters, vol. 473, no. 2, pp. 188–194, 2000
  40. Regulation of transient Na+ conductance by intra- and extracellular K+ in the human delayed rectifier K+ channel Kv1.5
    The Journal of Physiology, vol. 523, no. 3, pp. 575–591, 2000
  41. Modulation of slow inactivation in human cardiac Kv1.5 channels by extra- and intracellular permeant cations
    The Journal of Physiology, vol. 515, no. 2, pp. 315–329, 1999
  42. Gating current studies reveal both intra- and extracellular cation modulation of K+ channel deactivation
    The Journal of Physiology, vol. 515, no. 2, pp. 331–339, 1999
  43. Perspectives in Drug Discovery and Design, vol. 15/16, pp. 227–243, 1999
  44. Non-specific action of methoxamine on Ito, and the cloned channels hKv?1.5 and Kv?4.2
    British Journal of Pharmacology, vol. 126, no. 3, Article ID 0702335, 11 pages, 1999
  45. On the Mechanism by which 4-Aminopyridine Occludes Quinidine Block of the Cardiac K+ Channel, hKv1.5
    The Journal of General Physiology, vol. 111, no. 4, pp. 539–554, 1998
  46. The 1997 Stevenson Award Lecture. Cardiac K+channel gating: cloned delayed rectifier mechanisms and drug modulation
    Canadian Journal of Physiology and Pharmacology, vol. 76, no. 2, pp. 77–89, 1998
  47. Allosteric Effects of Permeating Cations on Gating Currents during K+ Channel Deactivation
    The Journal of General Physiology, vol. 110, no. 2, pp. 87–100, 1997
  48. Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia-dependent arrhythmias
    Drug Development Research, vol. 42, no. 3-4, pp. 198–210, 1997
  49. A computer simulation of the effect of heart rate on ion concentrations in the heart
    Journal of Theoretical Biology, vol. 132, no. 1, pp. 15–27, 1988